<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749747</url>
  </required_header>
  <id_info>
    <org_study_id>14-0038</org_study_id>
    <nct_id>NCT02749747</nct_id>
  </id_info>
  <brief_title>Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric</brief_title>
  <official_title>Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric: a Double-blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Introduction: Estrogen hormonal therapy associated or not with progestagen is the
           standard therapy for the treatment of hot flushes. However some women are not candidates
           for hormone replacement therapy for medical reasons or for choice.

        -  Main goal: Reducing the number of hot flushes per week

        -  Materials and Methods: A double-blind sulpiride versus placebo that includes selected
           randomized patients which show symptoms of menopause. Study conducted at Hospital de
           Clínicas de Porto Alegre (Brazil) for 8 weeks of intervention. The expected result is a
           significant reduction in the number of hot flushes / day evaluated by daily
           questionnaires
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be held 4 visits. The V0 (first one) to implement the consent form, review the
      inclusion and exclusion criteria and laboratory exams and deliver the diary book of hot
      flushes. The V1 (second visit) randomization and provide medication for the first 30 days.
      The V2 (third visit) to make the record diary of hot flushes already filled, to deliver new
      specifications and to provide medication for the last 30 days. The V3 (fourth visit) to
      evaluate the record diary of hot flushes already completed and to make a final evaluation of
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity records of hot flushes</measure>
    <time_frame>From baseline to eight weeks</time_frame>
    <description>Daily diary of symptoms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Menopausal Syndrome</condition>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>Sulpiride use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg sulpiride once a day use for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50mg placebo once a day use for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulpiride use</intervention_name>
    <description>50mg sulpiride once a day use for 60 days</description>
    <arm_group_label>Sulpiride use</arm_group_label>
    <other_name>Equilid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50mg placebo once a day use for 60 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women in postmenopausal women with at least five moderate to intense hot
             flushes per day

        Exclusion Criteria:

          -  Use of hormone replacement therapy or psychiatric drugs for at least 3 months

          -  Hypersensitivity to sulpiride

          -  Current or history of prolactin dependent tumor

          -  Treating breast cancer or treated

          -  Diagnosed or suspected pheochromocytoma

          -  Current use of levodopa

          -  Abnormal heart rhythm (QT prolongation, bradycardia low 55 beats per minute)

          -  Hypokalemia and other serious electrolyte disturbances

          -  Current or treated stroke

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Celeste Osorio Wender</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio Grande do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Pedro AO, Pinto Neto AM, Paiva LH, Osis MJ, Hardy E. [Age at natural menopause among Brazilian women: results from a population-based survey]. Cad Saude Publica. 2003 Jan-Feb;19(1):17-25. Epub 2003 Apr 1. Portuguese.</citation>
    <PMID>12700780</PMID>
  </reference>
  <reference>
    <citation>Vilodre LC, Moretto M, Kohek MB, Spritzer PM. [Premature ovarian failure: present aspects]. Arq Bras Endocrinol Metabol. 2007 Aug;51(6):920-9. Review. Portuguese.</citation>
    <PMID>17934658</PMID>
  </reference>
  <reference>
    <citation>De Lorenzi DR, Baracat EC, Saciloto B, Padilha I Jr. [Factors related to quality of life in post-menopause]. Rev Assoc Med Bras (1992). 2006 Sep-Oct;52(5):312-7. Portuguese.</citation>
    <PMID>17160304</PMID>
  </reference>
  <reference>
    <citation>Wender, M.C. et al. Consenso Brasileiro de Terapêutica Hormonal da Menopausa. SOBRAC - Leitura Médica. 2014.</citation>
  </reference>
  <reference>
    <citation>Oderich, C. L., Wender, M.C. Climatério. Revista Brasileira de Medicina. 69, 2012.</citation>
  </reference>
  <results_reference>
    <citation>Sussman M, Trocio J, Best C, Mirkin S, Bushmakin AG, Yood R, Friedman M, Menzin J, Louie M. Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records. BMC Womens Health. 2015 Aug 13;15:58. doi: 10.1186/s12905-015-0217-y.</citation>
    <PMID>26271251</PMID>
  </results_reference>
  <results_reference>
    <citation>Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015 Mar 10;(3):CD002229. doi: 10.1002/14651858.CD002229.pub4. Review.</citation>
    <PMID>25754617</PMID>
  </results_reference>
  <results_reference>
    <citation>Loprinzi CL, Stearns V, Barton D. Centrally active nonhormonal hot flash therapies. Am J Med. 2005 Dec 19;118 Suppl 12B:118-23.</citation>
    <PMID>16414336</PMID>
  </results_reference>
  <results_reference>
    <citation>Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015 Jun 18;7:615-24. doi: 10.2147/IJWH.S50804. eCollection 2015. Review.</citation>
    <PMID>26124682</PMID>
  </results_reference>
  <results_reference>
    <citation>Umland EM, Falconieri L. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health. 2012;4:305-19. doi: 10.2147/IJWH.S24614. Epub 2012 Jul 5.</citation>
    <PMID>22870045</PMID>
  </results_reference>
  <results_reference>
    <citation>Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health. 2010 Aug 9;2:123-35.</citation>
    <PMID>21072305</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruscky SB, Caldeira MV, Bueno JR. [Clinical trial with sulpiride]. Arq Neuropsiquiatr. 1974 Sep;32(3):234-9. Portuguese.</citation>
    <PMID>4408939</PMID>
  </results_reference>
  <results_reference>
    <citation>Simon JA, Chandler J, Gottesdiener K, Lazarus N, He W, Rosenberg E, Wagner JA, Denker AE. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine. Menopause. 2014 Sep;21(9):938-44. doi: 10.1097/GME.0000000000000218.</citation>
    <PMID>24569618</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>nonhormonal treatment</keyword>
  <keyword>sulpiride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

